UK Markets closed
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • FTSE 250

    18,636.98
    -29.80 (-0.16%)
     
  • AIM

    875.21
    -1.01 (-0.12%)
     
  • GBP/EUR

    1.1593
    -0.0018 (-0.16%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.5930%)
     
  • BTC-GBP

    15,736.67
    -163.52 (-1.03%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • DOW

    31,097.26
    +321.83 (+1.05%)
     
  • CRUDE OIL

    108.46
    +2.70 (+2.55%)
     
  • GOLD FUTURES

    1,812.90
    +5.60 (+0.31%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,813.03
    +29.26 (+0.23%)
     
  • CAC 40

    5,931.06
    +8.20 (+0.14%)
     

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030

·3-min read
ReportLinker
ReportLinker

KEY FINDINGS The global Alzheimer’s disease therapeutics & diagnostics market is anticipated to grow at a 6. 61% CAGR during the estimation period between 2022 to 2030. The market growth is accelerated by the rise in the pervasiveness of Alzheimer’s disease, emerging novel diagnostic technologies, and the increasing number of pipeline drugs.

New York, June 22, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030" - https://www.reportlinker.com/p05381495/?utm_source=GNW


MARKET INSIGHTS
Alzheimer’s is a neurodegenerative disease characterized by chronic inflammation and accumulation of beta-amyloid peptides.The elderly usually suffer from Alzheimer’s disease, which gradually damages their thinking skills and memory, eventually destroying their ability to perform the simplest daily tasks.

Alzheimer’s disease is the major reason for dementia among the older population. Therefore, the rising geriatric population is a key driver for the global Alzheimer’s disease therapeutics and diagnostics market.
Several novel diagnostics technologies have been discovered for Alzheimer’s disease (AD), including the invention that identifies mutated proteins in subcellular compartments. This invention describes these mutations that lead to the redistribution of crucial cellular organelles.
Furthermore, alteration of organelles distribution can be a powerful diagnostic tool, an assay to screen novel therapeutic compounds for Alzheimer’s disease.This technology’s advantage includes identifying mutated proteins, which are directly involved in the genesis of AD.

Thus, there is potential for providing a superior AD diagnosis compared to current diagnostic tests.

REGIONAL INSIGHTS
The global Alzheimer’s disease therapeutics & diagnostics market assessment entails the analysis of Europe, Asia-Pacific, North America, and Rest of World. The Asia-Pacific region is anticipated to propel with the highest CAGR by 2030, owing to the rapidly increasing geriatric population and government initiative to develop medicines to cure AD.

COMPETITIVE INSIGHTS
The competition in the global market is significantly high owing to the presence of generic medicines.Furthermore, strong competition exists among the key players in developing new diagnostics methodologies and treatments.

However, the industry is observing meaningful strategic partnerships to enhance market presence.
Some important global players include Merck & Co Inc, Cognoptix Inc, Eli Lilly & Company, Johnson & Johnson, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
2. AMARANTUS BIOSCIENCE HOLDINGS INC
3. BAXTER INTERNATIONAL INC
4. BIOGEN INC
5. COGNOPTIX INC
6. EISAI CO LTD
7. ELI LILLY & COMPANY
8. F HOFFMANN-LA ROCHE
9. GE HEALTHCARE
10. JOHNSON & JOHNSON
11. LUPIN LIMITED
12. MERCK & CO INC
13. NOVARTIS AG
14. PFIZER INC
15. SIEMENS HEALTHINEERS AG
16. SUN PHARMACEUTICALS INDUSTRIES LTD
17. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
18. ZYDUS CADILA
Read the full report: https://www.reportlinker.com/p05381495/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting